Patent application number | Description | Published |
20090220491 | Binding agents which inhibit myostatin - The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity. | 09-03-2009 |
20100330072 | Myostatin binding agents - The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity. | 12-30-2010 |
20120083442 | MYOSTATIN BINDING AGENTS - The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity. | 04-05-2012 |
20120129771 | PEPTIDES AND RELATED MOLECULES THAT MODULATE NERVE GROWTH FACTOR ACTIVITY - The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically active polypeptides comprising peptides linked to one or more Fc domains are provided. | 05-24-2012 |
20150044235 | CARRIER IMMUNOGLOBULINS - Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide. | 02-12-2015 |
Patent application number | Description | Published |
20090011497 | Peptides and related compounds having thrombopoietic activity - The present invention relates generally to novel peptides and related compounds that have thrombopoietic activity. The compounds of the invention may be used to increase production of platelets or platelet precursors (e.g. megakaryocytes) in a mammal. | 01-08-2009 |
20090054323 | Specific Binding Agents of Human Angiopoietin-2 - Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies. | 02-26-2009 |
20100240582 | Peptides and related molecules that modulate nerve growth factor activity - The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically active polypeptides comprising peptides linked to one or more Fc domains are provided. | 09-23-2010 |
20100240590 | PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1 - The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz | 09-23-2010 |
20100286060 | SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOEITIN-2 - Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies. | 11-11-2010 |
20120141499 | SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 - Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies. | 06-07-2012 |
20130158234 | SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 - Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies. | 06-20-2013 |
20140234334 | PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1 - The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz | 08-21-2014 |
20140275479 | SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOEITIN-2 - Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies. | 09-18-2014 |